Study Updates, Financial Strategy, Quarterly Report, Acquisition, and Presentation - Research Report on Vertex, Chimerix, Anika Therapeutics, Charles River, and Repros PR Newswire NEW YORK, October 23, 2013 NEW YORK, October 23, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Analysts' Corner announced new research reports highlighting Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), Chimerix, Inc. (NASDAQ: CMRX), Anika Therapeutics Inc. (NASDAQ: ANIK), Charles River Laboratories International, Inc. (NYSE: CRL), and Repros Therapeutics Inc. (NASDAQ: RPRX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Vertex Pharmaceuticals Incorporated Research Report On October 17, 2013, Vertex Pharmaceuticals Incorporated (Vertex) announced that the TRAFFIC and TRANSPORT Phase 3 studies of lumacaftor (VX-809) in combination with ivacaftor in people with two copies of the F508del mutation are fully enrolled. Vertex reported that the data from these studies are expected in mid-2014, and it plans to submit a New Drug Application (NDA) in the US and a Marketing Authorization Application (MAA) in Europe in H2 2014 for the combination of lumacaftor and ivacaftor. In its presentation made at the 27th Annual North American Cystic Fibrosis Conference (NACFC), the Company also reported updates on the multiple ongoing label-expansion studies for ivacaftor, ongoing and planned Phase 2 combination studies of lumacaftor and ivacaftor and VX-661 and ivacaftor, and research efforts aimed at beginning clinical development of a next-generation corrector. The Full Research Report on Vertex Pharmaceuticals Incorporated - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/e696_VRTX] -- Chimerix, Inc. Research Report On October 18, 2013, Chimerix, Inc. (Chimerix) announced the pricing of an underwritten public offering of 2.48 million shares of its common stock at a price to the public of $16.50 per share. According to Chimerix, all of the shares are being sold by certain existing stockholders, who have granted the underwriters a 30-day option to purchase up to an additional 371,549 shares of common stock to cover over-allotments, if any. Chimerix reported that it will not receive any proceeds from the sale of the shares, and the principal purposes of the offering are to facilitate an orderly distribution of shares and to increase the Company's public float. The Company further informed that Morgan Stanley & Co. LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering. The Full Research Report on Chimerix, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/2797_CMRX] -- Anika Therapeutics Inc. Research Report On October 15, 2013, Anika Therapeutics Inc. (Anika Therapeutics) announced that it will release its Q3 2013 results after the market close on Wednesday, October 30, 2013. The Company reported that it will host its Q3 2013 conference call on Thursday, October 31, 2013 at 9:00 a.m. ET. Anika Therapeutics stated that interested parties may access the live audio webcast as well as a replay through the Investor Relations section of the Company website. The Full Research Report on Anika Therapeutics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/ae5d_ANIK] -- Charles River Laboratories International, Inc. Research Report On October 7, 2013, Charles River Laboratories International, Inc. (Charles River) announced that it has successfully completed its acquisition of BRASS Pte. Ltd. (BRASS). According to Charles River, it aims to accelerate the growth of its portfolio of products and services in Asia by providing clients with state-of-the-art microbial detection and identification for manufacturing in the biopharmaceutical, medical device, and life sciences industries. The Company reported that BRASS will be renamed as Charles River Endotoxin and Microbial Detection Singapore Pte. Ltd. (Charles River Singapore), and will add to Charles River's presence in Asia, which includes sites in Korea, India, and China. The Full Research Report on Charles River Laboratories International, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/a37e_CRL] -- Repros Therapeutics Inc. Research Report On October 7, 2013, Repros Therapeutics Inc. (Repros) announced that the Sexual Medicine Society of North America (SMSNA) has accepted key data on Androxal for presentation at the annual meeting in New Orleans, Louisiana on November 21 to November 24, 2013. Repros reported that the data presented belong to the subset analyses of the double-blind, placebo and active control Phase 2 and 3 studies. Dr. Wayne Hellstrom, Professor of Urology and Chief of Andrology, Tulane University School of Medicine in New Orleans, said, "Selection of all three analyses for presentation at the premier sexual health meeting in the US, shows the increasing interest that the urological community has in the management of hypogonadism. The data presented not only highlight the potential utility of Androxal but also the limitations of existing therapy." The Full Research Report on Repros Therapeutics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/2334_RPRX] ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. AnalystsCorner.com SOURCE Analysts' Corner Contact: CONTACT PERSON: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
Study Updates, Financial Strategy, Quarterly Report, Acquisition, and Presentation - Research Report on Vertex, Chimerix, Anika
Press spacebar to pause and continue. Press esc to stop.